Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03879616 · ClinicalTrials.gov registry record · NA

Optimizing Gastrointestinal Procedure Appointments

A NA study of Gastrointestinal Disease, sponsored by Kaiser Permanente.

Completed
Registry status
NA
Development phase
15,974
Enrollment target
1
Study location

NCT03879616: Completed NA study of Gastrointestinal Disease, sponsored by Kaiser Permanente.

NCT03879616 is a NA study of Gastrointestinal Disease that has completed, run by Kaiser Permanente. The registered enrollment target is 15,974 participants, above the 134-participant average among 7 other Gastrointestinal Disease trials with a reported enrollment target (11821% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03879616, a NA study of Gastrointestinal Disease, has completed, sponsored by Kaiser Permanente.

COMPLETED
Registry status
NA
Development phase
15,974 participants
Enrollment target
1
Study location

Study Summary

This project will address the question: Does an "enhanced" IVR-T protocol differ in effectiveness from the standard IVR-T protocol in reducing missed appointments and late cancellations for GI endoscopy? Hypothesis: The enhanced IVR-T protocol will be more effective.

Primary Outcome

The primary outcome for the study will be "appointment loss," defined by GI leaders as the combined rate of prior day cancellations, same-day cancellations, and missed clinic appointments ("no shows"). The rationale for this outcome definition is that it is difficult to schedule new procedures within this time frame.

Conditions Studied

Interventions

  • BEHAVIORAL An Enhanced Reminder

Study Locations (1)

Colorado

  • Kaiser Permanente - Aurora

Trial Details

FieldValue
Enrollment Target 15,974 participants
Start Date 2019-03-08
Est. Completion 2021-12-31
Phase NA
Kaiser Permanente

294 total trials

What the finished NCT03879616 record still lists

NCT03879616 is an interventional study that assigns participants to a tested intervention. Its 15,974 participants enrollment target places it among the larger protocols in the corpus, above the 134-participant average among 7 other Gastrointestinal Disease trials with a reported enrollment target (11821% higher).

The record links to 1 condition, with Gastrointestinal Disease appearing as the primary indexed condition, and to 1 intervention - of which An Enhanced Reminder is the first listed.

NCT03879616 reports a single indexed study location in Colorado.

Frequently Asked Questions

What is clinical trial NCT03879616 about?

NCT03879616 is a clinical study titled "Optimizing Gastrointestinal Procedure Appointments". This project will address the question: Does an "enhanced" IVR-T protocol differ in effectiveness from the standard IVR-T protocol in reducing missed appointments and late cancellations for GI endoscopy? Hypothesis: The enhanced IVR-T protocol will be more effective.

What is the current status of trial NCT03879616?

This trial is currently completed. It is a NA study. The enrollment target is 15,974 participants. The study started on 2019-03-08. Estimated completion is 2021-12-31.

What conditions does trial NCT03879616 study?

This clinical trial studies the following conditions: Gastrointestinal Disease.

What interventions are being tested in trial NCT03879616?

The interventions under investigation include: An Enhanced Reminder (BEHAVIORAL).

Who is sponsoring clinical trial NCT03879616?

This trial is sponsored by Kaiser Permanente, which has 294 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03879616 being conducted?

This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Gastrointestinal Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01737528 · 16,000 participants

    STS/ACC Transcatheter Valve Therapy Registry (TVT Registry)

  • NCT06380114 · 16,000 participants · NA

    Stand Up 2 HPV: Standing Orders to Improve HPV Vaccination

  • NCT05447806 · 15,732 participants · NA

    Diabetes Clinical Decision Support

  • NCT06951867 · 16,640 participants

    Tezspire Cardiac Events PASS

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03879616, the US trial registry maintained by the National Library of Medicine. NCT03879616 (large enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.